Explore
Validate
LearnAB-279-NA
antibody from R&D Systems
Targeting: CCL2
GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF
Western blot
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AB-279-NA - Provider product page
- Provider
- R&D Systems
- Product name
- Human CCL2/JE/MCP-1 Antibody
- Antibody type
- Polyclonal
- Description
- Protein A or G purified. Detects human CCL2/JE/MCP-1 in direct ELISAs and Western blots. In direct ELISAs, approximately 15% cross-reactivity with recombinant canine MCP-1 is observed, and less than 1% cross-reactivity with recombinant human (rh) MCP-2, rhMCP-3, rhMCP-4, and recombinant mouse MCP-5 is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
P13500- Isotype
- IgG
- Vial size
- 1 mg
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.
Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells.
Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells.
Liu Z, Xu J, Li H, Zheng Y, He J, Liu H, Zhong Y, Lu Y, Hong B, Zhang M, Lin P, Du J, Hou J, Qian J, Kwak LW, Yi Q, Yang J
PloS one 2013;8(12):e82453
PloS one 2013;8(12):e82453
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.
Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E
Nature medicine 2011 Oct 30;17(11):1498-503
Nature medicine 2011 Oct 30;17(11):1498-503
Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells.
Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, Jensen MC
Journal of immunology (Baltimore, Md. : 1950) 2007 Sep 1;179(5):3332-41
Journal of immunology (Baltimore, Md. : 1950) 2007 Sep 1;179(5):3332-41
Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells.
Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, Jensen MC
Journal of immunology (Baltimore, Md. : 1950) 2007 Sep 1;179(5):3332-41
Journal of immunology (Baltimore, Md. : 1950) 2007 Sep 1;179(5):3332-41
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Chemotaxis Induced by CCL2/MCP-1 and Neutral-ization by Human CCL2/ MCP-1 Antibody. Recombinant Human CCL2/ MCP-1 (Catalog # 279-MC) chemoattracts BaF3 mouse pro-B cell line transfected with human CCR2A in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL2/ MCP-1 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CCL2/MCP-1 Polyclonal Antibody (Catalog # AB-279-NA). The ND50 is typically 50-100 µg/mL.
